Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Maternal arterial blood pH at the start of surgery
研究概览
简要总结
Myelomeningocele is a malformation with high incidence, and it consists in a neural tube defect. Fetal intrauterine surgery is an alternative for correction, and it improves the prognosis of the fetus, but has an increased risk of maternal complications and premature labor, as it can occur due to uterine stimulation. It is therefore essential that tocolysis is performed before, during and after surgery, and the most commonly used tocolytics are terbutaline and atosiban. Terbutaline has no specificity and may have several adverse effects such as maternal acidosis.
详细描述
The objective of the study was to evaluate maternal blood gas alterations among cases that used atosiban tocolytic agent and cases with terbutaline in in utero repair of myelomeningocele. It consists of a retrospective cohort study. It included 25 patients, who were divided into two groups, depending on which agent they received as main tocolytic agent during the intrauterine fetal myelomeningocele repair: terbutalineor atosiban. The primary outcome was maternal arterial pH at the end of surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Pregnant women over 18 years
- •Single fetus pregnancy
- •Fetus with myelomeningocele
- •Gestational age from 19 to 26
- •Fetus with normal karyotype
排除标准
- •Multiple pregnancy
- •Fetal abnormality not related to myelomeningocele
- •Kyphosis greater than or equal to 30 degrees
- •Placenta previa
- •Maternal disease that increases the risk of pregnancy (insulin-dependent DM, hypertension poorly controlled)
- •History of incompetent cervix
- •Carrier of HIV, hepatitis B or hepatitis C
- •Maternal-fetal isoimmunization
- •Uterine Alteration
- •Obesity (IMC greater than 30)
研究组 & 干预措施
Atosiban
Intravenous Atosiban as main tocolytic agent
干预措施: Atosiban (Drug)
Terbutaline
Intravenous Terbutaline as main tocolytic agent
干预措施: Terbutaline (Drug)
结局指标
主要结局
Maternal arterial blood pH at the start of surgery
时间窗: Right after intubation
Arterial blood pH
Maternal arterial blood pH at the end of surgery
时间窗: Before extubation
Arterial blood pH
Maternal arterial blood pH at 120 minutes after surgery
时间窗: Two hours after the end of surgery
Arterial blood pH
次要结局
- Short-term fetal repercussions(In the end of the surgery, before extubation)
- Long-term fetal repercussions(At the birth)
研究者
Hermann dos Santos Fernandes
Attending Anesthetist
University of Sao Paulo General Hospital